Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, Matsushita T, Hayashi F, Yamasaki R, Kuhle J, Kira JI.

Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160. Epub 2019 Aug 30.

PMID:
31471502
2.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group.

Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.

3.

Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.

Peng L, Bi C, Xia D, Mao L, Qian H.

Mult Scler Relat Disord. 2019 May;30:123-128. doi: 10.1016/j.msard.2019.02.009. Epub 2019 Feb 8.

4.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
5.

CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders.

Wei Y, Chang H, Li X, Du L, Xu W, Cong H, Yao Y, Zhang X, Yin L.

Biomed Res Int. 2018 Oct 22;2018:5381239. doi: 10.1155/2018/5381239. eCollection 2018.

6.

Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.

Wong YYM, Bruijstens AL, Barro C, Michalak Z, Melief MJ, Wierenga AF, van Pelt ED, Neuteboom RF, Kuhle J, Hintzen RQ.

Neurology. 2019 Sep 3;93(10):e968-e974. doi: 10.1212/WNL.0000000000008057. Epub 2019 Aug 5.

PMID:
31383792
7.

Neurofilament and glial fibrillary acidic protein in multiple sclerosis.

Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M.

Neurology. 2004 Nov 9;63(9):1586-90.

PMID:
15534240
8.

Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.

Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, Scher AI, Kuhle J, Ascherio A.

JAMA Neurol. 2019 Sep 13. doi: 10.1001/jamaneurol.2019.3238. [Epub ahead of print]

PMID:
31515562
9.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J.

J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1.

PMID:
21197541
10.

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.

Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, Airas L.

Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380. [Epub ahead of print]

PMID:
30570436
11.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

12.

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A.

Front Neurol. 2019 Mar 26;10:280. doi: 10.3389/fneur.2019.00280. eCollection 2019.

13.

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.

Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, Ziemssen T.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 8;6(3):e555. doi: 10.1212/NXI.0000000000000555. eCollection 2019 May.

14.

Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.

Onatsu J, Vanninen R, Jäkälä P, Mustonen P, Pulkki K, Korhonen M, Hedman M, Zetterberg H, Blennow K, Höglund K, Herukka SK, Taina M.

J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2242-2249. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008. Epub 2019 May 28.

PMID:
31151840
15.

Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.

Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ.

Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757. [Epub ahead of print]

PMID:
30912689
16.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
17.

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli Ö, Kuhle J, Benedict RH.

Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428. [Epub ahead of print]

PMID:
31610732
18.

Pre- and early postoperative GFAP serum levels in glioma and brain metastases.

Baumgarten P, Quick-Weller J, Gessler F, Wagner M, Tichy J, Forster MT, Foerch C, Seifert V, Mittelbronn M, Senft C.

J Neurooncol. 2018 Sep;139(3):541-546. doi: 10.1007/s11060-018-2898-1. Epub 2018 May 24.

PMID:
29797180
19.

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders.

Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, Helisalmi S, Haapasalo A, Koivumaa-Honkanen H, Herukka SK, Remes AM, Solje E.

J Neurol. 2019 Oct 8. doi: 10.1007/s00415-019-09567-8. [Epub ahead of print]

PMID:
31595378
20.

Increased serum IL-36β and IL-36γ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity.

Yang CS, Zhang QX, Deng Y, Zhou BJ, Zhang LJ, Li LM, Qi Y, Wang J, Yang L, Shi FD.

BMC Neurol. 2019 Aug 5;19(1):185. doi: 10.1186/s12883-019-1415-2.

Supplemental Content

Support Center